A Phase 3 interventional study of Somatropin in Growth Hormone Deficiency, sponsored by Pfizer. Completed at 19 sites in France. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 23rd largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 7th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
17 studies in Dwarfism, Pituitary by Pfizer: 1 open now, 2 under way, none of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 17 studies in Dwarfism, Pituitary by Pfizer, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 3, and was the 3rd registered.
Pfizer’s Dwarfism, Pituitary studies by the year they started, since 1997.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 17 in Dwarfism, Pituitary:
This tab as a report to print or save as PDF → With an account.
To estimate the evolution of height and growth rate over 5 years of growth hormone (GH) treatment To estimate the prognostic factors of growth rate with GH treatment To confirm the good clinical and biological safety of GH treatment in such children
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Somatropin
Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population
Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
Time frame: Baseline, Month 36
Change From Baseline in Height Standard Deviation Score (SD) for Chronological Age (CA) at Month 36: Per Protocol (PP) Population
Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
Time frame: Baseline, Month 36
Mean Height
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Mean Height Standard Deviation Score (SDS) for Bone Age (BA)
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Annual Growth Rate (AGR)
AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and re scaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). Yx refers to the value at particular timepoint x.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Growth Rate (GR) Standard Deviation Score (SDS) for Bone Age (BA)
GR SDS BA Yx = (GR Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. BA was estimated locally using an X-ray from the left wrist and hand.
Time frame: Month 12, 24, 36, 48, 60
Growth Rate (GR) Standard Deviation Score (SDS) for Chronological Age (CA)
GR SDS CA Yx = (GR Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Body Mass Index (BMI)
BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2).
Time frame: Baseline, Month 12, 24, 36, 48, 60
Change From Baseline in Height at Month 12, 24, 36, 48 and 60
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, 24, 48 and 60
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
Time frame: Baseline, Month 12, 24, 48, 60
Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, 24, 36, 48 and 60
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Change From Baseline in Bone Age (BA) at Month 12, 24, 36, 48 and 60
BA was estimated locally using an X-ray from the left wrist and hand.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Ratio of Bone Age (BA) to Chronological Age (CA)
BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.
Time frame: Baseline, Month 12, 24, 36, 48, 60
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs include both SAEs and non-SAEs.
Time frame: Baseline up to 28 days after last study treatment
Number of Participants With Significant Changes in Physical Examinations
Number of participants with clinically significant physical examinations changes since previous visit were reported. Physical examination including estimation of pubertal stage and blood pressure measurement;
Time frame: Baseline, Month 12, 24, 36, 48, 60, End of Treatment (EOT)
Number of Participants With at Least 1 Medical or Surgical History
Time frame: Screening
Number of Participants Who Received Concomitant Medications
Time frame: Baseline up to Month 60
Fasting Serum Insulin Like Growth Factor-1 (IGF-1) Levels
Time frame: Screening, Month 6, 12, 18, 24, 30, 36, 42, 48, 54, 60
Fasting and Postprandial Plasma Glucose Levels at Month 12, 24, 36, 48 and 60
Fasting and 2 hours plasma glucose levels were assessed using standard oral glucose tolerance test (OGTT).
Time frame: Screening, Month 12, 24, 36, 48, 60
| Milestone | Genotonorm |
|---|---|
| Started | 98 |
| Completed | 35 |
| Not completed | 63 |
| Withdrew: Other | 6 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Death | 3 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lack of efficacy | 7 |
| Withdrew: Study terminated by sponsor | 11 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Did not meet continuation criterion | 16 |
Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
| Standard Deviation Score (SDS) | Genotonorm |
|---|---|
| Baseline (n=58) | -2.91 ± 1.19 |
| Change at Month 36 (n=30) | 0.80 ± 1.03 |
Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
| SDS | Genotonorm |
|---|---|
| Baseline (n=21) | -2.86 ± 0.89 |
| Change at Month 36 (n=19) | 0.81 ± 1.18 |
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.
| centimeters (cm) | Genotonorm |
|---|---|
| Baseline (n=58) | 133.9 ± 15.7 |
| Month 12 (n=50) | 139.5 ± 16.8 |
| Month 24 (n=41) | 146.0 ± 16.4 |
| Month 36 (n=30) | 150.4 ± 16.0 |
| Month 48 (n=14) | 152.4 ± 16.0 |
| Month 60 (n=9) | 156.0 ± 11.3 |
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.
| SDS | Genotonorm |
|---|---|
| Baseline (n=51) | -0.29 ± 1.15 |
| Month 12 (n=40) | -0.36 ± 1.52 |
| Month 24 (n=29) | 0.11 ± 1.36 |
| Month 36 (n=24) | 0.14 ± 1.48 |
| Month 48 (n=13) | -0.26 ± 1.28 |
| Month 60 (n=7) | -0.19 ± 1.15 |
AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and re scaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). Yx refers to the value at particular timepoint x.
| cm/year | Genotonorm |
|---|---|
| Baseline (n=52) | 3.0 ± 2.0 |
| Month 12 (n=49) | 6.7 ± 2.6 |
| Month 24 (n=41) | 6.0 ± 2.7 |
| Month 36 (n=30) | 5.9 ± 2.7 |
| Month 48 (n=14) | 4.8 ± 2.5 |
| Month 60 (n=9) | 4.9 ± 3.0 |
GR SDS BA Yx = (GR Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. BA was estimated locally using an X-ray from the left wrist and hand.
| SDS | Genotonorm |
|---|---|
| Month 12 (n=36) | -0.13 ± 2.15 |
| Month 24 (n=25) | 0.07 ± 2.51 |
| Month 36 (n=20) | 0.05 ± 1.94 |
| Month 48 (n=11) | -1.00 ± 1.38 |
| Month 60 (n=7) | -0.43 ± 1.22 |
GR SDS CA Yx = (GR Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. GR in SDS was calculated using Sempe reference means and SD for GR. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
| SDS | Genotonorm |
|---|---|
| Baseline (n=52) | -2.04 ± 2.03 |
| Month 12 (n=49) | 1.77 ± 4.29 |
| Month 24 (n=41) | 5.26 ± 16.79 |
| Month 36 (n=29) | 3.64 ± 9.06 |
| Month 48 (n=13) | 0.93 ± 2.73 |
| Month 60 (n=9) | 1.40 ± 1.71 |
BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2).
| kg/m^2 | Genotonorm |
|---|---|
| Baseline (n=58) | 19.4 ± 3.6 |
| Month 12 (n=50) | 19.1 ± 3.1 |
| Month 24 (n=41) | 19.4 ± 3.0 |
| Month 36 (n=30) | 19.4 ± 2.4 |
| Month 48 (n=14) | 19.7 ± 3.0 |
| Month 60 (n=9) | 20.8 ± 3.3 |
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.
| cm | Genotonorm |
|---|---|
| Baseline (n=58) | 133.9 ± 15.7 |
| Change at Month 12 (n=50) | 6.8 ± 2.8 |
| Change at Month 24 (n=41) | 12.9 ± 4.7 |
| Change at Month 36 (n=30) | 18.8 ± 6.1 |
| Change at Month 48 (n=14) | 23.9 ± 8.5 |
| Change at Month 60 (n=9) | 30.3 ± 7.6 |
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12.
| SDS | Genotonorm |
|---|---|
| Baseline (n=58) | -2.91 ± 1.19 |
| Change at Month 12 (n=50) | 0.28 ± 0.57 |
| Change at Month 24 (n=41) | 0.57 ± 0.95 |
| Change at Month 48 (n=14) | 0.82 ± 1.42 |
| Change at Month 60 (n=9) | 0.75 ± 1.13 |
The standing height measurements were performed using a wall mounted device (example Harpenden Stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx; Yx refers to the value at particular timepoint x. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand.
| SDS | Genotonorm |
|---|---|
| Baseline (n=51) | -0.29 ± 1.15 |
| Change at Month 12 (n=36) | -0.02 ± 0.99 |
| Change at Month 24 (n=26) | 0.28 ± 1.18 |
| Change at Month 36 (n=21) | 0.31 ± 1.17 |
| Change at Month 48 (n=13) | -0.08 ± 1.30 |
| Change at Month 60 (n=7) | 0.01 ± 1.33 |
BA was estimated locally using an X-ray from the left wrist and hand.
| months | Genotonorm |
|---|---|
| Baseline (n=58) | 117.9 ± 34.6 |
| Change at Month 12 (n=37) | 17.8 ± 11.0 |
| Change at Month 24 (n=32) | 28.2 ± 17.9 |
| Change at Month 36 (n=23) | 36.5 ± 17.8 |
| Change at Month 48 (n=13) | 52.8 ± 21.2 |
| Change at Month 60 (n=7) | 70.0 ± 27.0 |
BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.
| ratio | Genotonorm |
|---|---|
| Baseline (n=58) | 0.78 ± 0.10 |
| Month 12 (n=37) | 0.82 ± 0.11 |
| Month 24 (n=32) | 0.80 ± 0.09 |
| Month 36 (n=23) | 0.79 ± 0.10 |
| Month 48 (n=13) | 0.81 ± 0.08 |
| Month 60 (n=7) | 0.85 ± 0.10 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs include both SAEs and non-SAEs.
| participants | Genotonorm |
|---|---|
| AEs | 84 |
| SAEs | 45 |
Number of participants with clinically significant physical examinations changes since previous visit were reported. Physical examination including estimation of pubertal stage and blood pressure measurement;
| participants | Genotonorm |
|---|---|
| Baseline (n=93) | 1 |
| Month 12 (n=93) | 16 |
| Month 24 (n=72) | 16 |
| Month 36 (n=52) | 5 |
| Month 48 (n=23) | 4 |
| Month 60 (n=12) | 2 |
| EOT (n=44) | 11 |
| participants | Genotonorm |
|---|---|
| Number of Participants With at Least 1 Medical or Surgical History | 67 |
| participants | Genotonorm |
|---|---|
| Number of Participants Who Received Concomitant Medications | 98 |
| nanogram per milliliter (ng/mL) | Genotonorm |
|---|---|
| Screening (n=93) | 335 ± 157 |
| Month 6 (n=63) | 604 ± 291 |
| Month 12 (n=71) | 538 ± 268 |
| Month 18 (n=47) | 624 ± 251 |
| Month 24 (n=62) | 579 ± 262 |
| Month 30 (n=50) | 559 ± 250 |
| Month 36 (n=44) | 511 ± 186 |
| Month 42 (n=22) | 555 ± 224 |
| Month 48 (n=21) | 581 ± 244 |
| Month 54 (n=16) | 593 ± 184 |
| Month 60 (n=10) | 501 ± 180 |
Fasting and 2 hours plasma glucose levels were assessed using standard oral glucose tolerance test (OGTT).
| milli mole per liter (mmol/L) | Genotonorm |
|---|---|
| Glucose Fasting: Screening (n=91) | 4.5 ± 0.7 |
| Glucose Fasting: Month 12 (n=69) | 4.6 ± 0.7 |
| Glucose Fasting: Month 24 (n=59) | 4.7 ± 0.6 |
| Glucose Fasting: Month 36 (n=45) | 4.6 ± 0.5 |
| Glucose Fasting: Month 48 (n=20) | 4.7 ± 0.4 |
| Glucose Fasting: Month 60 (n=14) | 4.5 ± 0.6 |
| Glucose Postprandial: Screening (n=94) | 5.6 ± 1.2 |
| Glucose Postprandial: Month 12 (n=66) | 6.1 ± 1.4 |
| Glucose Postprandial: Month 24 (n=59) | 6.1 ± 1.4 |
| Glucose Postprandial: Month 36 (n=41) | 6.4 ± 1.6 |
| Glucose Postprandial: Month 48 (n=19) | 6.1 ± 1.1 |
| Glucose Postprandial: Month 60 (n=13) | 6.3 ± 1.5 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Genotonorm | — | 45/98 (45.9%) | 81/98 (82.7%) |
| Event | Genotonorm |
|---|---|
| GastroenteritisInfections and infestations | 8/98 |
| Nephrotic syndromeRenal and urinary disorders | 7/98 |
| Renal failureRenal and urinary disorders | 5/98 |
| SepsisInfections and infestations | 3/98 |
| DeathGeneral disorders | 3/98 |
| DehydrationMetabolism and nutrition disorders | 3/98 |
| Urinary tract infectionInfections and infestations | 2/98 |
| VaricellaInfections and infestations | 2/98 |
| ProteinuriaRenal and urinary disorders | 2/98 |
| DiarrhoeaGastrointestinal disorders | 2/98 |
| Event | Genotonorm |
|---|---|
| Insulin-like growth factor increasedInvestigations | 13/98 |
| Nephrotic syndromeRenal and urinary disorders | 11/98 |
| DiarrhoeaGastrointestinal disorders | 9/98 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/98 |
| BronchitisInfections and infestations | 8/98 |
| AstheniaGeneral disorders | 8/98 |
| Glucose tolerance impairedMetabolism and nutrition disorders | 8/98 |
| HeadacheNervous system disorders | 8/98 |
| PyrexiaGeneral disorders | 7/98 |
| NasopharyngitisInfections and infestations | 6/98 |
Safety analysis set included all participants (including a site with GCP issues) who had received at least 1 study dose of growth hormone (GH).
| Age, Continuous(years) | Genotonorm |
|---|---|
| Mean | 11.8 ± 3.2 |
| Sex: Female, Male(Participants) | Genotonorm |
|---|---|
| Female | 24 |
| Male | 74 |
The record gives a start of Jan 2005, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone